Tascenso ODT (fingolimod lauryl sulfate) NDC 70709-065

NDC codes

FDA NDC Directory

Product NDC (as listed)70709-065Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70709-0065Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70709-065-30	70709006530	3 BLISTER PACK in 1 CARTON (70709-065-30) / 10 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACKMarketed from Feb 1, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Tascenso ODT
Generic name (nonproprietary): fingolimod lauryl sulfate
Active ingredients: Fingolimod lauryl sulfate — .5 mg/1
Dosage form: Tablet, Orally disintegrating
Route: Oral
Labeler: Cycle Pharmaceuticals Ltd
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 214962
Marketing start: Feb 1, 2023
Listing expires: Dec 31, 2027
Other FDA classes: Sphingosine 1-Phosphate Receptor Modulators (Mechanism)
Identifiers: Product ID 70709-065_fdba8834-a431-46b5-8dd2-5f57fb1efc79SPL ID fdba8834-a431-46b5-8dd2-5f57fb1efc79SPL set ID bf8e7f89-ea09-43c7-a7eb-e44724350721RxCUI 2610295, 2610302, 2626383, 2626385UNII J3HZQ9BE2SUPC 0370709062303
Pharmacologic class: Sphingosine 1-phosphate Receptor Modulator

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470709006530 followed by a unit qualifier and the quantity

Package 70709-0065-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 20, 2026.

Indications (excerpt from the label)

TASCENSO ODT is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. TASCENSO ODT is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 214962

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 214962
Product	Strength	Form · route	Labeler	Product NDC
Tascenso ODTfingolimod lauryl sulfate	Fingolimod lauryl sulfate .25 mg/1	Tablet, Orally disintegratingOral	Cycle Pharmaceuticals Ltd	70709-062